LIXTE Biotechnology Holdings (NASDAQ: LIXT) has reported significant progress in its first-quarter 2026 Form 10-Q filing, highlighting the continued advancement of its lead oncology candidate, LB-100, and strategic expansion through its recently acquired subsidiary, Liora Technologies Europe. The company noted expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy, as well as continued growth at Liora Technologies as it pursues broader strategic initiatives to strengthen its oncology pipeline and treatment development capabilities.
LB-100, LIXTE's first-in-class clinical PP2A inhibitor, has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies, potentially improving outcomes for patients with various cancers. The compound is part of a pioneering effort in an entirely new field of cancer biology—activation lethality—that is advancing a new treatment paradigm. LIXTE's novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora's proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
The company's strategic expansion and pipeline progress come at a critical time as LIXTE seeks to advance its oncology candidates through clinical development. The expansion of the ovarian cancer trial underscores the potential of LB-100 in combination with immunotherapies, a promising area in oncology research. With proof-of-concept trials ongoing, LIXTE is positioning itself to address unmet medical needs in hard-to-treat cancers.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. Additional information can be found at www.lixte.com. The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT.